oondi | Free Articles. Write for Cash.

Sanofi-Aventis' cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed. The French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxa...

Doctors report that higher levels of oxygen improve the odds that the babies will survive, but make it more likely that they’ll suffer from eye damage. But they also noted that a treatment used to help adults with sleep apnea is as effective as the traditional ventilator treatment for these babies and may cause fewer complications. The treatment uses a continuous positive airway pr...

By examining nationwide cancer registries and death certificates in three countries, doctors found that survival rates for men dropped from 11.3 percent in Sweden, to 9.3 percent in Norway, to 6.5 percent in England. The same pattern was seen in women, although they survived longer than men overall. The difference between countries was particularly striking in the first few months, and then ...

Researchers analyzed the cases of 229 babies born after 22 or 23 weeks of pregnancy, which is considered to be at the "margins of viability," according to the study authors. The babies were born in northern England between 1993 and 2007. Of the 210 babies who died, 34 percent lived for more than six hours. The average survival of babies who died despite receiving active treatment gradua...

The first meta-analysis of 34 studies involving almost 8,500 patients (and more than 3,300 deaths) showed that survival at five years was 64 percent for patients who had chemotherapy and surgery, and 60 percent for patients who had surgery alone. The second meta-analysis of 13 studies with 2,660 patients (1,909 deaths) showed that survival at five years was 33 percent for patients who h...

Oh Palm. Just a little over a year ago your future seemed so bright, so renewed. You walked away from CES 2009 reborn, held aloft by a completely innovative new mobile operating system, a striking piece of hardware, and a feeling amongst the press and investors that you were back in the game and playing to win. Now, less than a year and a half later, you've nearly returned to the dark and desperat...

In a study of 351 women with incident epithelial ovarian cancer, the researchers found that higher total fruit and vegetable consumption, higher vegetable consumption alone, and healthy grain consumption were associated with longer survival. High consumption of "less-healthy" meats was associated with shorter survival. The findings "suggest that food patterns three to five years prior to...

People who get all 36 sessions of cardiac rehabilitation that most Medicare plans cover are less likely to die or suffer a heart attack in the next three to four years than people who have fewer sessions, a new study finds. The research could encourage the multitudes of heart patients who don’t follow doctors’ orders to heed their advice. Only about one-fifth of heart patients even try...

It was the first big test of combining Herceptin and Tykerb. In a study of 300 patients, women receiving both drugs lived nearly five months longer than those given Tykerb alone. Doctors hope for an even bigger benefit in women with less advanced disease, and were elated at this much improvement for very sick women who were facing certain death. "We don’t see a lot that works in pati...

A gene-based test called Oncotype DX made by Genomic Health Inc may help identify a small group of women who are not likely to benefit from chemotherapy, a second study found. The main study proves that adding chemotherapy to treatment with the estrogen-blocking drug tamoxifen can help prevent cancer from coming back in women with estrogen-receptor positive breast cancers, the most commo...